Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »

For full access to this article login to GEN Select now.

Jun 10, 2014

NGS and Cancer Biomarker Market Metrics

Next-generation sequencing is on a growth trajectory.

NGS and Cancer Biomarker Market Metrics

The declining costs of NGS are the key driver for its utilization in the clinical setting. [genome.gov]

  • This report represents qualitative and quantitative metrics of the next-generation sequencing (NGS) landscape and frames it into the context of various biomarker classes.

    Highlights of ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »